-
ASH Global Perspectives | Prof. Fabio Efficace’s Team: Advances in Patient-Reported Outcomes in Hematology
In recent years, the field of hematologic malignancies has advanced at an unprecedented pace, with a steady emergence of novel therapies. While prolonging survival remains a central goal, patients’ quality…
-
New Breakthrough in Targeting BAFF Pathway: Ianalumab Significantly Prolongs Time to Treatment Failure in ITP Patients — A Detailed Look at VAYHIT 2
At the recently concluded American Society of Hematology (ASH) Annual Meeting in 2025, Dr. Hanny Al-Samkari from Massachusetts General Hospital presented the highly anticipated primary analysis of the VAYHIT 2 study. Presented as a Late-Breaking Abstract (LBA), this global, randomized, double-blind, Phase 3 clinical trial evaluated the efficacy and safety of combining the novel BAFF…
-
Breaking Diagnostic Bottlenecks: The IBMDX Study Reveals 37% Diagnostic Yield and Health Economic Value of Whole Genome Sequencing (WGS) in Inherited Bone Marrow Failure Syndromes
At the 2025 American Society of Hematology (ASH) Annual Meeting, Dr. Lucy Fox from the Peter MacCallum Cancer Centre (Australia) presented the highly anticipated results of the IBMDX study. This landmark trial evaluated the clinical utility and economic impact of “Upfront Whole Genome Sequencing (WGS)” in patients with suspected Inherited Bone Marrow Failure Syndromes (IBMFS).…
-
HR of 0.17! Tech-Dara: A Potent BCMA/CD38 Dual-Targeting Immunotherapy Combination Leads a New Paradigm in Second-Line MM Treatment—MAJEStec-3 Study Heavily Released
At the Late-Breaking Abstract (LBA) session of the 2025 American Society of Hematology (ASH) Annual Meeting, Dr. María-Victoria Mateos, representing the research team, unveiled the highly anticipated results of the MAJEStec-3 study. This marks the first reported Phase III clinical trial of a BCMA-targeted bispecific antibody. Comparing the combination of Teclistamab and Daratumumab (“Tech-Dara”) against…
-
80% Reduction in Risk of Disease Progression or Death! Stunning Head-to-Head Phase III Data of Pirtobrutinib in First-Line CLL/SLL
At the 2025 American Society of Hematology (ASH) Annual Meeting, Professor Wojciech Jurczak from the Maria Sklodowska-Curie National Research Institute of Oncology (Poland) presented the highly anticipated results of a global Phase III clinical trial. This study is the first head-to-head comparison evaluating the efficacy and safety of the non-covalent BTK inhibitor, pirtobrutinib, against the…
-
Breaking Ex Vivo Limitations: In Vivo Gene Delivery CAR-T Therapy (KLN-1010) Achieves 100% MRD Negativity in RRMM Patients Without Lymphodepletion
At the 67th American Society of Hematology (ASH) Annual Meeting in 2025, a groundbreaking Late-Breaking Abstract (LBA) presented by Professor Phoebe Joy Ho (Royal Prince Alfred Hospital, Australia) signaled a potential paradigm shift in the treatment of multiple myeloma. The preliminary results from the Phase 1 inMMyCAR study of KLN-1010—the first in vivo anti-BCMA CAR-T…
-
Prof. Hanny Al-Samkari on the VEHIT-2 Phase III ITP Trial
In this video, Prof. Hanny Al-Samkari of Harvard Medical School shares key insights from the VEHIT-2 Phase III randomized trial evaluating ianalumab in early second-line immune thrombocytopenia (ITP). He discusses…
-
ASH Peak Dialogue | Professors Jing-Zhou Hou & Dehui Zou:Decoding Breakthroughs at the Frontiers of Lymphoma and Sharing New Sino-US Practices
Lymphoma diagnosis and treatment are entering a phase of accelerated evolution, with breakthrough therapies and innovative research continuously reshaping clinical practice. From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was grandly held in Orlando. At this year’s congress, multidimensional and in-depth innovations emerged across both aggressive…
Connecting Medical Expertise through Media